Physician profile
Brad Carter
NPI 1902801590
$12,561.83
in general payments reported to CMS, 2019-2025
42 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $331 · 2021: $1,154 · 2022: $1,593 · 2023: $5,634 · 2024: $1,865 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,621 · Consulting Fee: $2,700 · Travel and Lodging: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,621.09 |
| Consulting Fee | $2,700.00 |
| Travel and Lodging | $1,365.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $4,536.44 | 2022-2023 | |
| Fresenius USA Marketing, INC. | $1,342.66 | 2019-2025 | Velphoro, Crit-Line, Velphoro |
| Vifor Pharma, INC. | $585.28 | 2019-2025 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $571.44 | 2023-2025 | |
| Amgen INC. | $568.12 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Glaxosmithkline, LLC. | $534.24 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $524.73 | 2019-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $351.48 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $339.91 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $326.30 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $314.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.73 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $231.53 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $215.88 | 2020-2025 | Terlivaz |
| Ardelyx, INC. | $194.49 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.